查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1942509

2026年全球癌症诊断市场报告

Cancer Diagnostics Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

がん诊断市场の规模は近年急速に拡大しております。2025年の255亿米ドルから2026年には285亿8,000万米ドルへと、CAGR12.1％で成长が见込まれております。过去数年间の成长は、世界のがん罹患率の上昇、肿疡学调査への投资増加、病院诊断インフラの拡充、画像诊断に基づくがん検出法の普及拡大、检查室の自动化进歩などが要因とされています。

がん诊断市场规模は今后数年间で急速な成长が见込まれております。2030年には446亿9,000万米ドルに达し、CAGRは11.8％となる见込みです。予测期间における成长は、个别化がん治疗への需要増加、次世代定序诊断の普及拡大、人口全体を対象としたがん検诊プログラムの拡充、AIを活用した肿疡诊断への投资拡大、多がん検出検査における継続的な技术革新などが要因となります。予测期间における主な动向としては、分子诊断およびコンパニオン诊断の采用拡大、がん検出におけるAIの统合増加、バイオマーカーベース検査の利用拡大、ハイスループット诊断プラットフォームの拡充、早期がん検诊への注力强化などが挙げられます。

预计未来几年，不断增长的医疗费用支出将推动癌症诊断市场的成长。医疗费用支出是指政府、企业和个人用于医疗程序、住院治疗、药物和公共卫生措施的总资金。医疗费用支出需求的成长主要是由于需要长期且昂贵治疗的慢性疾病日益普遍。不断增长的医疗保健医疗费用支出透过促进先进筛检技术的应用和扩大早期检测服务的覆盖范围，为癌症诊断提供了支持。对现代化设备和专业检查室的投资提高了诊断准确性，实现了及时干预，并改善了患者的治疗效果。例如，根据英国国家统计局2024年5月发布的数据，2023年医疗保健总支出名目值将增加5.6%，比2022年增加0.9%。因此，不断增长的医疗费用支出正在推动癌症诊断市场的成长。

肺癌发生率的不断上升也是推动癌症诊断市场发展的关键因素。肺癌是一种异常细胞在肺组织中不受控制地生长，形成肿瘤并转移到身体其他部位的疾病。癌症诊断设备对于肺癌的检测、诊断和后续观察至关重要，在帮助医护人员确定癌症的存在、类型和分期以及製定治疗方案方面发挥关键作用。例如，美国临床肿瘤学会（ASCO）在2023年3月估计，2023年美国将确诊238,340例肺癌病例，高于2022年的236,000例。因此，肺癌发生率的上升正在推动癌症诊断市场的扩张。

目录

第一章执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球癌症诊断市场：吸引力评分及分析
  • 成长潜力分析、竞争评估、策略契合度评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 主要原料、资源和供应商清单
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章 全球市场趋势与策略

  • 关键技术和未来趋势
    • 人工智慧（AI）和自主人工智慧
    • 生物技术、基因组学和精准医学
    • 数位化、云端运算、巨量资料、网路安全
    • 工业4.0和智慧製造
    • 物联网、智慧基础设施和互联生态系统
  • 主要趋势
    • 分子诊断和伴随诊断的广泛应用
    • 人工智慧在癌症检测的应用进展
    • 扩大基于生物标记的检测应用
    • 扩展高通量诊断平台
    • 人们越来越关注癌症早期筛检

第五章 终端用户产业市场分析

  • 医院
  • 诊断检查室
  • 癌症研究所
  • 专业肿瘤中心
  • 学术医疗机构

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及新冠疫情对市场的影响

第七章 全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球癌症诊断市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 全球癌症诊断市场规模、比较及成长率分析
  • 全球癌症诊断市场表现：规模与成长，2020-2025年
  • 全球癌症诊断市场预测：规模与成长，2025-2030年，2035年预测

第八章 全球潜在市场总量（TAM）

第九章 市场细分

  • 副产品
  • 伴随诊断、分子诊断
  • 透过方法
  • 切片检查、内视镜检查、肿瘤生物标记检测、影像诊断
  • 透过使用
  • 子宫颈癌、乳癌、肝癌、血癌、肾臟癌、结肠癌、胰臟癌、卵巢癌、黑色素瘤及其他适应症
  • 最终用户
  • 癌症研究机构、诊断检查室、医院和其他最终用户
  • 按类型细分：伴随诊断
  • 基于生物标记的伴随诊断、基于基因检测的伴随诊断、基于免疫组织化学的伴随诊断、基于PCR的伴随诊断和其他伴随诊断
  • 按类型细分：分子诊断
  • 聚合酵素链锁反应（PCR）诊断、次世代定序（NGS）诊断、原位杂合反应诊断、基于微阵列的诊断、DNA或RNA萃取试剂盒以及其他分子诊断

第十章 区域与国家分析

  • 全球癌症诊断市场：依地区、绩效及预测划分，2020-2025年、2025-2030年预测、2035年预测
  • 全球癌症诊断市场：依国家、绩效及预测划分，2020-2025年、2025-2030年预测、2035年预测

第十一章 亚太市场

第十二章：中国市场

第十三章 印度市场

第十四章 日本市场

第十五章：澳洲市场

第十六章 印尼市场

第十七章 韩国市场

第十八章 孟加拉国市场

第十九章 泰国市场

第二十章 越南市场

第21章 马来西亚市场

第22章 新加坡市场

第23章：菲律宾市场

第24章 香港市场

第25章：纽西兰市场

第二十六章 台湾市场

第27章 东南亚市场

第28章 西欧市场

第29章英国市场

第三十章：德国市场

第31章：法国市场

第32章：义大利市场

第33章：西班牙市场

第34章：奥地利市场

第35章：比利时市场

第三十六章：丹麦市场

第37章 芬兰市场

第38章：爱尔兰市场

第39章：荷兰市场

第四十章：挪威市场

第四十一章：葡萄牙市场

第42章：瑞典市场

第42章 瑞士市场

第43章 东欧市场

第四十四章：俄罗斯市场

第45章：捷克市场

第四十六章：波兰市场

第四十七章：罗马尼亚市场

第四十八章：乌克兰市场

第49章 北美市场

第五十章：美国市场

第51章 加拿大市场

第五十二章：墨西哥市场

第53章 南美洲市场

第五十四章：巴西市场

第55章 智利市场

第五十六章：阿根廷市场

第五十七章：哥伦比亚市场

第五十八章 秘鲁市场

第五十九章 中东市场

第六十章：沙乌地阿拉伯市场

第61章：以色列市场

第62章 伊朗市场

第63章 土耳其市场

第64章：阿联酋市场

第65章：非洲市场

第66章 埃及市场

第六十七章：尼日利亚市场

第68章 南非市场

第69章 市场监理与投资环境

第七十章：竞争格局与公司概况

  • 癌症诊断市场：竞争格局与市场占有率（2024 年）
  • 癌症诊断市场：公司估值矩阵
  • 癌症诊断市场：公司概况
    • Abbott Laboratories
    • Becton Dickinson and Company
    • Hologic
    • GE Healthcare Ltd.
    • Thermo Fisher Scientific

第71章：其他领先和创新企业

  • Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies

第72章：全球市场竞争基准分析与仪錶板

第73章：重大併购

第74章：高潜力市场国家、细分市场与策略

  • 2030年癌症诊断市场：提供新机会的国家
  • 2030年癌症诊断市场：新兴细分市场机会
  • 2030年癌症诊断市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第75章附录

简介目录
Product Code: ME3MCDIA04_G26Q1

Cancer diagnostics involves the processes, tests, and technologies used to detect the presence of cancer in individuals. This area includes various methods aimed at identifying, staging, and characterizing cancer, enabling timely and effective treatment.

The primary offerings within the cancer diagnostics sector include companion diagnostics and molecular diagnostics. Molecular diagnostics involve laboratory procedures to detect particular proteins, genes, or molecules indicating the presence of cancer. Diagnostic methods in cancer assessments encompass biopsies, endoscopies, tumor biomarker tests, and imaging. These diagnostic tools cater to various applications, including cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others. They are utilized by diverse end-users like cancer research institutes, diagnostic laboratories, hospitals, and related entities.

Tariffs are influencing the cancer diagnostics market by increasing costs of imported sequencing platforms, imaging systems, reagents, consumables, and laboratory automation equipment. Hospitals, diagnostic laboratories, and research institutes in North America and Europe are most affected due to heavy reliance on imported diagnostic technologies, while Asia-Pacific faces higher procurement costs for advanced testing platforms. These tariffs are raising testing costs and slowing laboratory expansion plans. At the same time, they are encouraging regional manufacturing of diagnostic kits, localized reagent production, and increased focus on cost-efficient diagnostic innovation.

The cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cancer diagnostics market statistics, including cancer diagnostics industry global market size, regional shares, competitors with a cancer diagnostics market share, detailed cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer diagnostics industry. This cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer diagnostics market size has grown rapidly in recent years. It will grow from $25.5 billion in 2025 to $28.58 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to rising global cancer prevalence, increased investments in oncology research, expansion of hospital diagnostic infrastructure, growing adoption of imaging-based cancer detection, improvements in laboratory automation.

The cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $44.69 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing demand for personalized cancer therapies, rising adoption of next-generation sequencing diagnostics, expansion of population-wide cancer screening programs, growing investments in AI-enabled oncology diagnostics, continuous innovation in multi-cancer detection tests. Major trends in the forecast period include increasing adoption of molecular and companion diagnostics, rising integration of ai in cancer detection, growing use of biomarker-based testing, expansion of high-throughput diagnostic platforms, enhanced focus on early cancer screening.

Rising healthcare expenditure is expected to drive growth in the cancer diagnostics market in the coming years. Healthcare expenditure encompasses the total financial resources allocated to medical treatments, hospital care, medications, and public health initiatives by governments, businesses, and individuals. The growing demand for healthcare spending is largely driven by the increasing prevalence of chronic diseases, which require long-term and often costly care. Higher healthcare expenditure supports cancer diagnostics by enabling the adoption of advanced screening technologies and expanding access to early detection services. Investments in modern equipment and specialized laboratories enhance diagnostic accuracy, facilitate timely intervention, and improve patient outcomes. For example, in May 2024, the UK Office for National Statistics reported that total healthcare expenditure increased by 5.6% in nominal terms in 2023, representing a 0.9% rise compared to 2022. Therefore, rising healthcare expenditure is fueling the growth of the cancer diagnostics market.

The increasing incidence of lung cancer is another key factor driving the cancer diagnostics market. Lung cancer originates in the lung tissues, where abnormal cells grow uncontrollably, forming tumors that may spread to other parts of the body. Cancer diagnostic devices are essential for detecting, diagnosing, and monitoring lung cancer, helping healthcare professionals determine its presence, type, stage, and guide treatment decisions. For instance, in March 2023, the American Society of Clinical Oncology (ASCO), a US-based organization, estimated that 238,340 people in the United States would be diagnosed with lung cancer in 2023, up from 236,000 cases in 2022. Therefore, the rising incidence of lung cancer is contributing to the expansion of the cancer diagnostics market.

Major companies operating in the cancer diagnostics market are focusing on artificial intelligence (AI)-driven innovations to improve diagnostic precision and efficiency. AI-based tools analyze tissue samples and clinical data to aid pathologists in identifying cancerous and non-cancerous regions. For example, in March 2023, Qritive, a Singapore-based developer of AI-powered diagnostic solutions, launched QAi Prostate. This advanced AI-powered tool assists in prostate cancer diagnosis by using machine learning algorithms to accurately detect and classify malignant and benign areas in prostate tissue samples, supporting pathologists in making informed diagnostic and treatment decisions.

Major companies operating in the cancer diagnostics market are Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, Invitae Corporation, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics

North America was the largest region in the cancer diagnostics market in 2025. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cancer diagnostics market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

The cancer diagnostics market consists of sales of pathology-based instruments (slide staining systems, tissue processing systems, cell processors, PCR instruments, NGS instruments, and other pathology-based instruments), imaging Instruments (CT systems, ultrasound systems, MRI systems, mammography systems, and nuclear imaging systems) and biopsy instruments that are used for the diagnosis of cancer. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Products: Companion Diagnostics; Molecular Diagnostics
  • 2) By Method: Biopsy; Endoscopy; Tumor Biomarker Tests; Imaging
  • 3) By Application: Cervical Cancer; Breast Cancer; Liver Cancer; Blood Cancer; Kidney Cancer; Colorectal Cancer; Pancreatic Cancer; Ovarian Cancer; Melanoma; Other Applications
  • 4) By End-User: Cancer Research Institutes; Diagnostic Laboratories; Hospitals; Other End Users
  • Subsegments:
  • 1) By Companion Diagnostics: Biomarker-Based Companion Diagnostics; Genetic Testing-Based Companion Diagnostics; Immunohistochemistry-Based Companion Diagnostics; PCR-Based Companion Diagnostics; Other Companion Diagnostics;
  • 2) By Molecular Diagnostics: Polymerase Chain Reaction (PCR) Diagnostics; Next-Generation Sequencing (NGS) Diagnostics; In Situ Hybridization Diagnostics; Microarray-Based Diagnostics; DNA Or RNA Extraction Kits; Other Molecular Diagnostics
  • Companies Mentioned: Abbott Laboratories; Becton Dickinson and Company; Hologic; GE Healthcare Ltd.; Thermo Fisher Scientific; Siemens Healthcare GmbH; Biogenex Laboratories; Veracyte; PathAI; Bio-Rad Laboratories; BioChain; DiagnoCure; Illumina; Myriad Genetics; CompanionDx; Epic Sciences; Genomic Health; Affymetrix; Agilent Technologies; Adaptive Biotechnologies; Biocartis; Biocept; Cancer Genetics Inc.; Caris Life Sciences; Cepheid; Epigenomics AG; Exact Sciences; Foundation Medicine; GenMark Diagnostics; Guardant Health; HalioDX; Invitae Corporation; NanoString Technologies; Natera; NeoGenomics; Oncura Inc.; PerkinElmer; Personal Genome Diagnostics; Qiagen; Roche Diagnostics
  • Countries: China; India; Japan; Australia; Indonesia; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; Taiwan; New Zealand; UK; Germany; France; Italy; Spain; Austria; Belgium; Denmark; Finland; Ireland; Netherlands; Norway; Portugal; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Cancer Diagnostics Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Cancer Diagnostics Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Cancer Diagnostics Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Cancer Diagnostics Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Artificial Intelligence & Autonomous Intelligence
    • 4.1.2 Biotechnology, Genomics & Precision Medicine
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Molecular And Companion Diagnostics
    • 4.2.2 Rising Integration Of Ai In Cancer Detection
    • 4.2.3 Growing Use Of Biomarker-Based Testing
    • 4.2.4 Expansion Of High-Throughput Diagnostic Platforms
    • 4.2.5 Enhanced Focus On Early Cancer Screening

5. Cancer Diagnostics Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Diagnostic Laboratories
  • 5.3 Cancer Research Institutes
  • 5.4 Specialty Oncology Centers
  • 5.5 Academic Medical Institutions

6. Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Cancer Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Cancer Diagnostics Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Cancer Diagnostics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Cancer Diagnostics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Cancer Diagnostics Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Cancer Diagnostics Market Segmentation

  • 9.1. Global Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Companion Diagnostics, Molecular Diagnostics
  • 9.2. Global Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging
  • 9.3. Global Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications
  • 9.4. Global Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users
  • 9.5. Global Cancer Diagnostics Market, Sub-Segmentation Of Companion Diagnostics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Biomarker-Based Companion Diagnostics, Genetic Testing-Based Companion Diagnostics, Immunohistochemistry-Based Companion Diagnostics, PCR-Based Companion Diagnostics, Other Companion Diagnostics
  • 9.6. Global Cancer Diagnostics Market, Sub-Segmentation Of Molecular Diagnostics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Polymerase Chain Reaction (PCR) Diagnostics, Next-Generation Sequencing (NGS) Diagnostics, In Situ Hybridization Diagnostics, Microarray-Based Diagnostics, DNA Or RNA Extraction Kits, Other Molecular Diagnostics

10. Cancer Diagnostics Market Regional And Country Analysis

  • 10.1. Global Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Cancer Diagnostics Market

  • 11.1. Asia-Pacific Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Cancer Diagnostics Market

  • 12.1. China Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Cancer Diagnostics Market

  • 13.1. India Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Cancer Diagnostics Market

  • 14.1. Japan Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Cancer Diagnostics Market

  • 15.1. Australia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Cancer Diagnostics Market

  • 16.1. Indonesia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Cancer Diagnostics Market

  • 17.1. South Korea Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Bangladesh Cancer Diagnostics Market

  • 18.1. Bangladesh Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. Thailand Cancer Diagnostics Market

  • 19.1. Thailand Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Vietnam Cancer Diagnostics Market

  • 20.1. Vietnam Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. Malaysia Cancer Diagnostics Market

  • 21.1. Malaysia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Singapore Cancer Diagnostics Market

  • 22.1. Singapore Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. Philippines Cancer Diagnostics Market

  • 23.1. Philippines Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Hong Kong Cancer Diagnostics Market

  • 24.1. Hong Kong Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. New Zealand Cancer Diagnostics Market

  • 25.1. New Zealand Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Taiwan Cancer Diagnostics Market

  • 26.1. Taiwan Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Taiwan Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. South East Asia Cancer Diagnostics Market

  • 27.1. South East Asia Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 27.2. South East Asia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. Western Europe Cancer Diagnostics Market

  • 28.1. Western Europe Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. Western Europe Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. UK Cancer Diagnostics Market

  • 29.1. UK Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Germany Cancer Diagnostics Market

  • 30.1. Germany Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. France Cancer Diagnostics Market

  • 31.1. France Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Italy Cancer Diagnostics Market

  • 32.1. Italy Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Spain Cancer Diagnostics Market

  • 33.1. Spain Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Austria Cancer Diagnostics Market

  • 34.1. Austria Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Belgium Cancer Diagnostics Market

  • 35.1. Belgium Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

36. Denmark Cancer Diagnostics Market

  • 36.1. Denmark Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

37. Finland Cancer Diagnostics Market

  • 37.1. Finland Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

38. Ireland Cancer Diagnostics Market

  • 38.1. Ireland Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

39. Netherlands Cancer Diagnostics Market

  • 39.1. Netherlands Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

40. Norway Cancer Diagnostics Market

  • 40.1. Norway Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

41. Portugal Cancer Diagnostics Market

  • 41.1. Portugal Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

42. Sweden Cancer Diagnostics Market

  • 42.1. Sweden Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

42. Switzerland Cancer Diagnostics Market

  • 42.1. Switzerland Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

43. Eastern Europe Cancer Diagnostics Market

  • 43.1. Eastern Europe Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 43.2. Eastern Europe Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

44. Russia Cancer Diagnostics Market

  • 44.1. Russia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

45. Czech Republic Cancer Diagnostics Market

  • 45.1. Czech Republic Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

46. Poland Cancer Diagnostics Market

  • 46.1. Poland Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

47. Romania Cancer Diagnostics Market

  • 47.1. Romania Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

48. Ukraine Cancer Diagnostics Market

  • 48.1. Ukraine Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

49. North America Cancer Diagnostics Market

  • 49.1. North America Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 49.2. North America Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

50. USA Cancer Diagnostics Market

  • 50.1. USA Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 50.2. USA Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

51. Canada Cancer Diagnostics Market

  • 51.1. Canada Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 51.2. Canada Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

52. Mexico Cancer Diagnostics Market

  • 52.1. Mexico Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 52.2. Mexico Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

53. South America Cancer Diagnostics Market

  • 53.1. South America Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 53.2. South America Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

54. Brazil Cancer Diagnostics Market

  • 54.1. Brazil Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

55. Chile Cancer Diagnostics Market

  • 55.1. Chile Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

56. Argentina Cancer Diagnostics Market

  • 56.1. Argentina Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

57. Colombia Cancer Diagnostics Market

  • 57.1. Colombia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

58. Peru Cancer Diagnostics Market

  • 58.1. Peru Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

59. Middle East Cancer Diagnostics Market

  • 59.1. Middle East Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 59.2. Middle East Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

60. Saudi Arabia Cancer Diagnostics Market

  • 60.1. Saudi Arabia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

61. Israel Cancer Diagnostics Market

  • 61.1. Israel Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

62. Iran Cancer Diagnostics Market

  • 62.1. Iran Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

63. Turkey Cancer Diagnostics Market

  • 63.1. Turkey Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

64. United Arab Emirates Cancer Diagnostics Market

  • 64.1. United Arab Emirates Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

65. Africa Cancer Diagnostics Market

  • 65.1. Africa Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 65.2. Africa Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

66. Egypt Cancer Diagnostics Market

  • 66.1. Egypt Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

67. Nigeria Cancer Diagnostics Market

  • 67.1. Nigeria Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

68. South Africa Cancer Diagnostics Market

  • 68.1. South Africa Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

69. Cancer Diagnostics Market Regulatory and Investment Landscape

70. Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 70.1. Cancer Diagnostics Market Competitive Landscape And Market Share 2024
    • 70.1.1. Top 10 Companies (Ranked by revenue/share)
  • 70.2. Cancer Diagnostics Market - Company Scoring Matrix
    • 70.2.1. Market Revenues
    • 70.2.2. Product Innovation Score
    • 70.2.3. Brand Recognition
  • 70.3. Cancer Diagnostics Market Company Profiles
    • 70.3.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 70.3.2. Becton Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis
    • 70.3.3. Hologic Overview, Products and Services, Strategy and Financial Analysis
    • 70.3.4. GE Healthcare Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 70.3.5. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis

71. Cancer Diagnostics Market Other Major And Innovative Companies

  • Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies

72. Global Cancer Diagnostics Market Competitive Benchmarking And Dashboard

73. Key Mergers And Acquisitions In The Cancer Diagnostics Market

74. Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 74.1 Cancer Diagnostics Market In 2030 - Countries Offering Most New Opportunities
  • 74.2 Cancer Diagnostics Market In 2030 - Segments Offering Most New Opportunities
  • 74.3 Cancer Diagnostics Market In 2030 - Growth Strategies
    • 74.3.1 Market Trend Based Strategies
    • 74.3.2 Competitor Strategies

75. Appendix

  • 75.1. Abbreviations
  • 75.2. Currencies
  • 75.3. Historic And Forecast Inflation Rates
  • 75.4. Research Inquiries
  • 75.5. The Business Research Company
  • 75.6. Copyright And Disclaimer